Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XCSOA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ST8176AA1
|
|||||
| Synonyms |
ST 8176AA1; Trastuzumab-HDACi ADC
Click to Show/Hide
|
|||||
| Organization |
Alfasigma SpA
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
4.6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
ST7612AA1
|
Payload Info | ||||
| Therapeutic Target |
Histone deacetylase 1 (HDAC1)
|
Target Info | ||||
| Linker Name |
Maleimide-thiol linker
|
Linker Info | ||||
| Conjugate Type |
HDACi-based payload was conjugated to cysteines of trastuzumab.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.